HPV Associated Disorders Market Analysis, Market Size, Product Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2026

The global human papillomavirus (HPV) associated disorders market is projected to exhibit moderate growth through the forecast period, driven by the emergence of biologics and rising incidence of HPV associated diseases. Proactive government initiatives and steady growth in consumer awareness are likely to promote higher growth in this market.

There are more than 100 strains of HPV, out of which 13 are high-risk or cancerous. High vs low risk HPV strains are determined by the activated gene - E6 or E7. HPV infections are the most prevalent sexually transmitted infections. Unprotected sex, multiple sex partners, and a compromised immune system are some key causative factors for HPV related diseases.

The market is segmented by indications. HPV causes a wide array of diseases, including cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, and genital warts. Cervical cancer is one of the largest indications in this market, supported by strong commercial performances of Avastin and Keytruda.

The market is further segmented on the basis of therapy into prevention and treatment. Vaccines remain the mainstay of preventive strategy for HPV infections. The treatment landscape is gradually shifting towards a targeted therapeutic approach. On the basis of sales channel, the market is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Some of the major players in the global HPV associated disorders market include Merck & Co., Inc.; GlaxoSmithKline plc; F. Hoffmann-La Roche Ltd; Pfizer, Inc.; Allergan plc; AstraZeneca plc; Biocon Ltd.; and Eli Lilly and Company.